Last €257.00 EUR
Change Today -2.45 / -0.95%
Volume 174.0
As of 11:22 AM 08/21/14 All times are local (Market data is delayed by at least 15 minutes).

biogen idec inc (IDP) Snapshot

Open
€258.61
Previous Close
€259.46
Day High
€260.60
Day Low
€257.00
52 Week High
08/20/14 - €262.85
52 Week Low
08/21/13 - €152.75
Market Cap
60.7B
Average Volume 10 Days
636.8
EPS TTM
--
Shares Outstanding
236.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BIOGEN IDEC INC (IDP)

biogen idec inc (IDP) Details

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of multiple sclerosis (MS), neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. It provides AVONEX to treat relapsing MS; TYSABRI to treat relapsing forms of MS and Crohn’s disease; RITUXAN for treating relapsed or refractory, follicular, CD20-positive, and B-cell Non-Hodgkin’s lymphoma (NHL); FUMADERM to treat severe plaque psoriasis in adult patients; FAMPYRA, an oral compound for the improvement of walking in adult patients with MS; TECFIDERA for the treatment of MS; and GAZYVA, an injection for intravenous infusion that treats an untreated chronic lymphocytic leukemia. The company’s products that completed Phase III clinical trials comprise ELOCTATE and ALPROLIX, an inherited disorder that inhibits blood coagulations; and Peginterferon beta-1a to prolong the effects and reduce the dosing frequency of interferon beta-1a. Its products under Phase III clinical trials consist of Daclizumab, a monoclonal antibody in relapsing MS; TYSABRI for secondary progressive MS; and GA101, a monoclonal antibody for chronic lymphocytic leukemia and NHL. The company’s Phase II clinical trial products include Anti-LINGO for optic neuritis; STX-100 for idiopathic pulmonary fibrosis; Neublastin for neuropathic pain; and ANTI-TWAEK for lupus nephritis. Its Phase I clinical trial products comprise BIIB037 for Alzheimer's disease; BIIB037 for MS; and Anti-CD40 Ligand for general lupus, as well as Phase 1b/2a clinical trial products include ISIS-SMNRx for spinal muscular atrophy. Biogen Idec Inc. has collaboration agreements with Genentech, Inc.; Acorda Therapeutics, Inc.; Sangamo BioSciences; and Swedish Orphan Biovitrum AB. The company was formerly known as IDEC Pharmaceuticals Corporation and changed its name to Biogen Idec Inc. in November 2003. Biogen Idec Inc. was founded in 1985 and is headquartered in Cambridge, Massachusetts.

Founded in 1985

biogen idec inc (IDP) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $1.5M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $745.2K
Executive Vice President of Global Commercial...
Total Annual Compensation: $675.1K
Executive Vice President of Research & Develo...
Total Annual Compensation: $766.8K
Executive Vice President of Pharmaceutical Op...
Total Annual Compensation: $625.6K
Compensation as of Fiscal Year 2013.

biogen idec inc (IDP) Key Developments

Biogen Idec Inc. Gets OK for New MS Drug

Scrambling to stay ahead of the competition in bringing multiple sclerosis drugs to market, Biogen Idec Inc. won US regulatory approval to sell a new type of injectable drug that treats adults with the most common form of the neurodegenerative disease. Food and Drug Administration regulators approved the Cambridge biotech's application to market the drug, called Plegridy, as a longer-lasting treatment for US patients with relapsing-remitting multiple sclerosis. The approval came less than a month after the European Commission approved Biogen Idec's medicine for sale in 28 countries across the Atlantic. Multiple sclerosis is a chronic autoimmune disorder affecting the central nervous systems of at least 400,000 people in the United States and more than 2.3 million globally. It disrupts communication between the brain and other parts of the body, over time causing muscle weakness, loss of balance, and a progressive decline in physical functions.

Biogen Idec's PLEGRIDY (Peginterferon beta-1a) Approves in the US for the Treatment of Multiple Sclerosis

Biogen Idec announced that the U.S. Food and Drug Administration has approved PLEGRIDY (peginterferon beta-1a), a new treatment for people with relapsing forms of multiple sclerosis. PLEGRIDY, the only pegylated beta interferon approved for use in RMS, is dosed once every two weeks and can be administered subcutaneously with the PLEGRIDY PEN, a new, ready-to-use autoinjector, or a prefilled syringe. The FDA approval of PLEGRIDY is based on results from one of the pivotal studies of beta interferon conducted, ADVANCE, which involved more than 1,500 MS patients. ADVANCE was a two-year, Phase 3, placebo-controlled (in year one) study that evaluated the efficacy and safety of PLEGRIDY administered subcutaneously. The analysis for all primary and secondary efficacy endpoints occurred at the end of year one. After the first year, patients on placebo received PLEGRIDY for the duration of the study. In the first year of the ADVANCE clinical trial, PLEGRIDY dosed once every two weeks significantly reduced annualized relapse rate (ARR) at one year by 36% compared to placebo (p=0.0007). PLEGRIDY reduced the risk of 12-week confirmed disability progression, as measured by the Expanded Disability Status Scale, by 38% (p=0.0383) compared to placebo. PLEGRIDY also significantly reduced the number of new gadolinium-enhancing [Gd+] lesions by 86% (p<0.0001) and reduced new or newly enlarging T2-hyperintense lesions by 67% (p<0.0001) compared to placebo. The most common adverse reactions were injection site reaction, flu-like illness, fever, headache, muscle pain, chills, injection site pain, and weakness, injection site itching and joint pain. The ADVANCE two-year safety data were consistent with safety results observed in year one.

Biogen Idec Announces European Commission Grants Marketing Authorization for PLEGRIDY(TM) (peginterferon beta-1a) as Treatment for Adults with Relapsing-Remitting Multiple Sclerosis

Biogen Idec announced that the European Commission (EC) has granted marketing authorization for PLEGRIDY(TM) (peginterferon beta-1a) as a treatment for adults with relapsing-remitting multiple sclerosis (RRMS), the most common form of multiple sclerosis (MS). PLEGRIDY is dosed once every two weeks and is administered subcutaneously with the PLEGRIDY PEN, a new ready-to-use autoinjector, or a prefilled syringe. PLEGRIDY, the only pegylated interferon approved for use in RRMS, has been proven to significantly reduce important measures of disease activity, including number of relapses, MRI brain lesions, and disability progression. The EC approval of PLEGRIDY is based on results from one of the pivotal studies of a beta interferon conducted, ADVANCE, which involved more than 1,500 patients with relapsing forms of MS. In the ADVANCE clinical trial, PLEGRIDY, dosed once every two weeks, significantly reduced annualized relapse rate (ARR) at one year by 36% compared to placebo (p=0.0007). PLEGRIDY reduced the risk of sustained disability progression confirmed at twelve weeks by 38% (p=0.0383) and at twenty four weeks by 54% (p=0.0069, post-hoc analysis). In addition, the number of gadolinium-enhancing [Gd+] lesions was significantly reduced by 86% (p<0.0001) compared to placebo. Results over two years of ADVANCE confirm that its robust efficacy was maintained beyond the placebo-controlled first year of the study.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IDP:GR €257.00 EUR -2.45

IDP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IDP.
View Industry Companies
 

Industry Analysis

IDP

Industry Average

Valuation IDP Industry Range
No financial data is available for IDP.
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOGEN IDEC INC, please visit www.biogenidec.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.